1. Signaling Pathways
  2. Epigenetics
    JAK/STAT Signaling
    Stem Cell/Wnt
  3. JAK
  4. JAK Inhibitors

JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

JAK Inhibitors
Product Name JAK1 JAK2 JAK3 Tyk2 JAK Purity
Ruxolitinib
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.99%
Tofacitinib
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.96%
Ruxolitinib phosphate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
  99.89%
Baricitinib
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.93%
Fedratinib  
JAK2, IC50: 3 nM
JAK2(V617F), IC50: 3 nM
      98.62%
Tofacitinib citrate
JAK1, IC50: 112 nM
JAK2, IC50: 20 nM
JAK3, IC50: 1 nM
    99.92%
BMS-986165
JAK1 JH2, IC50: 1 nM
   
Tyk2 JH2, IC50: 0.2 nM
  99.76%
AZD-1480
JAK1, IC50: 1.3 nM
JAK2, IC50: 0.4 nM
      99.37%
WP1066  
JAK2
      99.67%
Pacritinib
JAK1, IC50: 1280 nM
JAK2V617F, IC50: 19 nM
JAK2wt, IC50: 23 nM
JAK3, IC50: 520 nM
Tyk2, IC50: 50 nM
  99.66%
Momelotinib
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    98.11%
CHZ868  
JAK2, IC50: 110 nM
      98.33%
Filgotinib
JAK1, IC50: 10 nM
JAK2, IC50: 28 nM
JAK3, IC50: 810 nM
Tyk2, IC50: 116 nM
  99.64%
AT9283  
JAK2, IC50: 1.2 nM
JAK3, IC50: 1.1 nM
    99.61%
Itacitinib
JAK1
        99.97%
Peficitinib
JAK1, IC50: 3.9 nM
JAK2, IC50: 5 nM
JAK3, IC50: 0.7 nM
Tyk2, IC50: 4.8 nM
  99.43%
PF-06651600    
JAK3, IC50: 33.1 nM
    99.98%
Cerdulatinib
JAK1, IC50: 12 nM
JAK2, IC50: 6 nM
JAK3, IC50: 8 nM
Tyk2, IC50: 0.5 nM
  99.00%
Gandotinib  
JAK2, IC50: 3 nM
JAK3, IC50: 48 nM
Tyk2, IC50: 44 nM
  99.96%
Pyridone 6
Murine JAK1, IC50: 15 nM
JAK2, IC50: 1 nM
JAK3, IC50: 5 nM
Tyk2, IC50: 1 nM
  98.04%
Cucurbitacin I  
JAK2
      >98.0%
Delgocitinib
JAK1, IC50: 2.8 nM
JAK2, IC50: 2.6 nM
JAK3, IC50: 13 nM
Tyk2, IC50: 58 nM
  99.14%
Lestaurtinib  
JAK2, IC50: 0.9 nM
      99.82%
TG101209  
JAK2, IC50: 6 nM
JAK3, IC50: 169 nM
    98.94%
Oclacitinib maleate
JAK1, IC50: 10 nM
JAK2, IC50: 18 nM
JAK3, IC50: 99 nM
Tyk2, IC50: 84 nM
  99.53%
Abrocitinib
JAK1, IC50: 29 nM
JAK2, IC50: 803 nM
 
Tyk2, IC50: 1253 nM
  99.79%
CEP-33779  
JAK2, IC50: 1.8 nM
JAK3, IC50: 150 nM
    98.04%
BMS-911543
JAK1, IC50: 75 nM
JAK2, IC50: 1.1 nM
JAK3, IC50: 360 nM
Tyk2, IC50: 66 nM
  98.12%
SAR-20347
JAK1, IC50: 23 nM
JAK2, IC50: 26 nM
JAK3, IC50: 41 nM
Tyk2, IC50: 0.6 nM
  97.00%
Ilginatinib
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  95.88%
Itacitinib adipate
JAK1
        99.37%
PF-06700841 P-Tosylate
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
    99.66%
Baricitinib phosphate
JAK1, IC50: 5.9 nM
JAK2, IC50: 5.7 nM
JAK3, IC50: 560 nM
Tyk2, IC50: 53 nM
  99.49%
AZ960  
JAK2, Ki: 0.45 nM
JAK2, IC50: <3 nM
JAK3, IC50: 9 nM
    >98.0%
TyK2-IN-2      
Tyk2
  99.41%
NVP-BSK805 dihydrochloride
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
  99.36%
Decernotinib
JAK1, Ki: 11 nM
JAK2, Ki: 13 nM
JAK3, Ki: 2.5 nM
Tyk2, Ki: 11 nM
  98.91%
FM381    
JAK3, IC50: 127 pM
    98.41%
JANEX-1    
JAK3, IC50: 78 μM
    99.84%
ZM39923 hydrochloride
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
    >98.0%
WHI-P154    
JAK3, IC50: 1.8 μM
    98.92%
XL019  
JAK2, IC50: 2.2 nM
JAK3, IC50: 214.2 nM
    >98.0%
Tyk2-IN-5      
Tyk2 JH2, Ki: 0.086 nM
  99.78%
Ilginatinib maleate
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  97.04%
JAK3-IN-1
JAK1, IC50: 896 nM
JAK2, IC50: 1050 nM
JAK3, IC50: 4.8 nM
    99.98%
JAK/HDAC-IN-1
JAK1, IC50: 4.8 nM
JAK2, IC50: 4 nM
JAK3, IC50: 7.4 nM
Tyk2, IC50: 49 nM
  98.04%
WHI-P97    
JAK3, IC50: 11 μM
    99.48%
Ilginatinib hydrochloride
JAK1, IC50: 33 nM
JAK2, IC50: 0.72 nM
JAK3, IC50: 39 nM
Tyk2, IC50: 22 nM
  98.02%
PF-06700841
JAK1, IC50: 17 nM
JAK2, IC50: 77 nM
JAK3, IC50: 6.9 μM
   
JAK1-IN-3
JAK1, IC50: 73 nM
        99.32%
Protosappanin A  
JAK2
      98.88%
GLPG0634 analog    
JAK3, IC50: <100 nM
Tyk2, IC50: <100 nM
  98.00%
Momelotinib sulfate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
    >96.0%
NSC 42834  
JAK2-WT, IC50: 15 μM
JAK2-V617F, IC50: 28 μM
      95.5%
NVP-BSK805
JAK1 JH1, IC50: 31.63 nM
JAK2 JH1, IC50: 0.48 nM
FL JAK2 V617F, IC50: 0.56 nM
FL JAK2 wt, IC50: 0.58 nM
JAK3 JH1, IC50: 18.68 nM
TYK2 JH1, IC50: 10.76 nM
 
JAK1-IN-4
JAK1, IC50: 85 nM
JAK2, IC50: 12.8 μM
     
JAK2/FLT3-IN-1
JAK1, IC50: 26 nM
JAK2, IC50: 0.7 nM
JAK3, IC50: 39 nM
   
JAK1-IN-7
JAK1
       
Tyk2-IN-7      
Tyk2 JH2, IC50: 0.00053 μM
Tyk2 JH2, Ki app: 0.00007 μM
 
JAK-IN-4        
JAK
PF-06263276
JAK1, IC50: 2.2 nM
JAK2, IC50: 23.1 nM
JAK3, IC50: 59.9 nM
Tyk2, IC50: 29.7 nM
 
JAK-IN-3
JAK1, IC50: 5 nM
JAK2, IC50: 70 nM
JAK3, IC50: 3 nM
Tyk2, IC50: 34 nM
 
JAK3 covalent inhibitor-1    
JAK3, IC50: 11 nM
   
JAK3-IN-6    
JAK3, IC50: 0.15 nM
    98.07%
BMS-066      
Tyk2, IC50: 72 nM
 
Momelotinib Mesylate
JAK1, IC50: 11 nM
JAK2, IC50: 18 nM
JAK3, IC50: 155 nM
   
Ruxolitinib sulfate
JAK1, IC50: 3.3 nM
JAK2, IC50: 2.8 nM
JAK3, IC50: 428 nM
Tyk2, IC50: 19 nM
 
ZM39923
JAK1, pIC50: 4.4
 
JAK3, pIC50: 7.1
   
JAK3-IN-7    
JAK3, IC50: 0.01 μM